Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
364 active trials6 approved drugs33 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,279 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06370013 | Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors | available | — | — | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 4, 2026source: clinicaltrials